Praxis Precision Medicines Inc

PRAX

Healthcare|Biotechnology|USA

$323.81

-8.39 (-2.52%)

Tangible Book

$50.61

Earnings Power

$6.56

Clinical Trials (17)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety	Epileptic Encephalopathy, SCN2A Encephalopathy	P3	Recruiting	40	Open-label	1mg elsunersen, 0.5mg elsunersen
NCT06999902 Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)	Focal Seizure	P2P3	Recruiting	230	RCT, Double-blind	20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
NCT05818553 A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)	SCN2A Encephalopathy, SCN8A Encephalopathy	P2P3	Active	77	RCT, Double-blind	PRAX-562
NCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine	Developmental and Epileptic Encephalopathy 1	P3	Recruiting	160	RCT, Double-blind	1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo
NCT07505004 Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures	Focal Epilepsy	P3	Recruiting	300	RCT, Double-blind	40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo
NCT05737784 A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy	SCN2A-DEE, Epilepsy	P1P2	Recruiting	60	RCT, Double-blind	PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses
NCT06908356 An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures	Focal Onset Seizure, Primary Generalized Epilepsy	P2	Recruiting	50	Open-label	30mg PRAX-628
NCT06087276 Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)	Essential Tremor	P3	By Invite	1,000	RCT, Double-blind	60 mg ulixacaltamide, Placebo
NCT04832425 A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder	Major Depressive Disorder	P2P3	Completed	216	RCT, Double-blind	PRAX-114, Placebo
NCT07287163 Clinical Trial of Vormatrigine in Adult Patients With Epilepsy	Epilepsy, Tonic-Clonic, Focal Seizure	P3	By Invite	700	Open-label	vormatrogine
NCT05021978 A Clinical Trial of PRAX-944 in Participants With Essential Tremor	Essential Tremor	P2	Completed	24	RCT, Double-blind	Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo
NCT05021991 A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor	Essential Tremor	P2	Completed	133	RCT, Double-blind	100 mg PRAX-944, 60 mg PRAX-944, Placebo, Flexibly dosed 20 mg to 100 mg PRAX-944
NCT05260541 A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder	Post-traumatic Stress Disorder, Post Traumatic Stress Disorder	P2	Terminated	11	RCT, Double-blind	60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114
NCT05387642 A Clinical Trial of PRAX-114 in Participants With Essential Tremor	Essential Tremor	P2	Withdrawn	—	RCT, Double-blind	10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114
NCT04969510 A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder	Major Depressive Disorder	P2	Completed	110	RCT, Double-blind	10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114, 60 mg PRAX-114, Placebo
NCT06840925 A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628	Healthy	P1	Not Yet Recruiting	16	RCT, Open-label	PRAX-628
NCT05407727 A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	SCN2A-DEE, Epilepsy		Completed	5	—	—